image credit: Pxfuel

FDA Approves American Gene Technologies (AGT) to Move Forward with Phase 1 Clinical Trial of HIV Cure Program

August 11, 2020

Via: BioSpace

American Gene Technologies (AGT) announced today approval by the Food and Drug Administration (FDA) to begin Phase 1, the first human clinical trial for AGT’s lead HIV program. AGT will conduct its Phase 1 study at clinical sites in the Baltimore/D.C. area, and has named Washington Health Institute, University of Maryland, Institute of Human Virology and Georgetown University as its initial trial sites. These sites are expected to begin enrollment in September 2020. AGT hopes to report initial data before the end of the year.

Read More on BioSpace